TY - JOUR
KW - GBM
KW - GBM-on-a-chip
KW - disease modeling
KW - Drug screening
KW - Tumor Microenvironment
AU - Surjendu Maity
AU - Tamanna Bhuyan
AU - Christopher Jewell
AU - Satoru Kawakita
AU - Saurabh Sharma
AU - Huu Tuan Nguyen
AU - Alireza Hassani Najafabadi
AU - Menekse Ermis
AU - Natashya Falcone
AU - Junjie Chen
AU - Kalpana Mandal
AU - Danial Khorsandi
AU - Can Yilgor
AU - Auveen Choroomi
AU - Emily Torres
AU - Marvin Mecwan
AU - Johnson V. John
AU - Mohsen Akbari
AU - Zhaohui Wang
AU - Diogo Moniz-Garcia
AU - Alfredo Quiñones-Hinojosa
AU - Vadim Jucaud
AU - Mehmet Remzi Dokmeci
AU - Ali Khademhosseini
AB - Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood-brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ-on-a-chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM-on-a-chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM-on-a-chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM-on-a-chip models.
BT - Small
DO - 10.1002/smll.202405511
IS - n/a
LA - en
N2 - Glioblastoma (GBM) is an aggressive form of cancer, comprising ≈80% of malignant brain tumors. However, there are no effective treatments for GBM due to its heterogeneity and the presence of the blood-brain barrier (BBB), which restricts the delivery of therapeutics to the brain. Despite in vitro models contributing to the understanding of GBM, conventional 2D models oversimplify the complex tumor microenvironment. Organ-on-a-chip (OoC) models have emerged as promising platforms that recapitulate human tissue physiology, enabling disease modeling, drug screening, and personalized medicine. There is a sudden increase in GBM-on-a-chip models that can significantly advance the knowledge of GBM etiology and revolutionize drug development by reducing animal testing and enhancing translation to the clinic. In this review, an overview of GBM-on-a-chip models and their applications is reported for drug screening and discussed current challenges and potential future directions for GBM-on-a-chip models.
EP - 2405511
T2 - Small
TI - Recent Developments in Glioblastoma-On-A-Chip for Advanced Drug Screening Applications
UR - https://onlinelibrary.wiley.com/doi/abs/10.1002/smll.202405511
VL - n/a
Y2 - 2024-11-27
SN - 1613-6829
ER -